GlaxoSmithKline PakistanKAR:GLAXO +1.66%92 Days Payable is 29.82 as of Mar. 2026, which is 7% above its 10-year median of 27.89. GuruFocus rates KAR:GLAXO with a GF Score™ of 92/100 and a GF Value™ of ₨324.26 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 921 Drug Manufacturers companies, GlaxoSmithKline Pakistan ranks worse than 84.8% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KAR:GLAXO vs ZTS, UTHR, VTRS: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, GlaxoSmithKline Pakistan's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GlaxoSmithKline Pakistan Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pakistan's Days Payable distribution charts can be found below:
* The bar in red indicates where GlaxoSmithKline Pakistan's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
GlaxoSmithKline Pakistan's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GlaxoSmithKline Pakistan (KAR:GLAXO) has a Days Payable of 29.82 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on GlaxoSmithKline Pakistan and its competitors. This is near median its historical median of 27.89. Over the past decade, GlaxoSmithKline Pakistan's Days Payable has ranged from 23.27 to 68.42. According to the industry distribution chart, GlaxoSmithKline Pakistan ranks #781 out of 921 companies in the Drug Manufacturers industry, placing it in the top 84.8%.
Is GlaxoSmithKline Pakistan's Days Payable too high?
GlaxoSmithKline Pakistan's current Days Payable of 29.82 is near median its 10-year median of 27.89. Over the past 10 years, this metric has ranged from a low of 23.27 to a high of 68.42. The Drug Manufacturers industry median Days Payable is 90.69. GlaxoSmithKline Pakistan's value of 29.82 is 67.1% below this industry median. Based on the distribution chart, GlaxoSmithKline Pakistan ranks #781 out of 921 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, GlaxoSmithKline Pakistan has a GF Score™ of 92/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pakistan's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, GlaxoSmithKline Pakistan ranks #781 out of 921 companies for Days Payable. This places GlaxoSmithKline Pakistan in the lower half of its industry. The industry median Days Payable is 90.69. GlaxoSmithKline Pakistan's value of 29.82 is 67.1% below this benchmark. Historically, GlaxoSmithKline Pakistan's own Days Payable has ranged from 23.27 to 68.42 over the past decade. While the company's 10-year median is 27.89 vs. the industry median of 90.69, GlaxoSmithKline Pakistan has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.69, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GlaxoSmithKline Pakistan's current Days Payable of 29.82 is 67.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on GlaxoSmithKline Pakistan and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GlaxoSmithKline Pakistan's current Days Payable is 29.82, which is near median its own 10-year median of 27.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pakistan stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pakistan (KAR:GLAXO) is currently considered Modestly Overvalued. The stock's GF Value™ is ₨324.26, compared to a current price of ₨370.25 — trading 14.2% above its estimated fair value. The current Days Payable is 29.82, which is near median its 10-year median of 27.89 and 67.1% below the Drug Manufacturers industry median of 90.69. GlaxoSmithKline Pakistan's overall GF Score™ is 92/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For GlaxoSmithKline Pakistan (KAR:GLAXO), the current Days Payable is 29.82 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GlaxoSmithKline Pakistan (KAR:GLAXO) Overvalued in 2026?
Based on GuruFocus' analysis, GlaxoSmithKline Pakistan stock appears to be overvalued.
The current stock price of ₨370.25 is trading 14.2% above its estimated GF Value™ of ₨324.26.
GuruFocus considers GlaxoSmithKline Pakistan to be Modestly Overvalued.
Key valuation signals for KAR:GLAXO:
Days Payable: 29.82 (near median its 10-year median of 27.89)
GF Value™: ₨324.26 vs. price of ₨370.25 (14.2% above fair value)
Industry Position: 67.1% below the Drug Manufacturers median (#781 of 921)
No single metric tells the full story. See the KAR:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GlaxoSmithKline Pakistan Ltd is engaged in the research, development, and manufacturing of pharmaceutical medicines, vaccines, and consumer healthcare products. It is involved in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular, and Vitamins therapy areas. The operating business divisions are Pharmaceuticals and Consumer Healthcare. The pharmaceutical brands of the company include Augmentin, Seretide, Amoxicillin, Velosef, Zantac, and Calpol, and prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix, and Cervarix. The company operates in single segment which is the Pharmaceuticals segment.
92GF Score
Get the complete analysis for KAR:GLAXO
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:GLAXO has been successfully added to your 
